Connect Biopharma HoldingsCNTB -0.47%7 PB Ratio is 3.12 as of Jun. 25, 2026, which is 0% below its 10-year median of 3.13. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Connect Biopharma Holdings ranks worse than 54.34% on this metric.
The historical rank and industry rank for Connect Biopharma Holdings's PB Ratio or its related term are showing as below:
CNTB'
s PB Ratio Range Over the Past 10 Years
Min: 1.21 Med: 3.13 Max: 4.64
Current: 3.12
During the past 7 years, Connect Biopharma Holdings's highest PB Ratio was 4.64. The lowest was 1.21. And the median was 3.13.
CNTB's PB Ratio is ranked worse than 54.34% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs CNTB: 3.12
During the past 12 months, Connect Biopharma Holdings's average Book Value Per Share Growth Rate was -54.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -36.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Connect Biopharma Holdings was -30.40% per year. The lowest was -36.20% per year. And the median was -33.30% per year.
Back to Basics: PB Ratio
Connect Biopharma Holdings (NAS:CNTB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Connect Biopharma Holdings PB Ratio Related Terms
Connect Biopharma Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Connect Biopharma Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Connect Biopharma Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Connect Biopharma Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Connect Biopharma Holdings (CNTB) has a PB Ratio of 3.12 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Connect Biopharma Holdings and its competitors. This is near median its historical median of 3.13. Over the past decade, Connect Biopharma Holdings' PB Ratio has ranged from 1.21 to 4.64. According to the industry distribution chart, Connect Biopharma Holdings ranks #670 out of 1233 companies in the Biotechnology industry, placing it in the top 54.3%.
Is Connect Biopharma Holdings' PB Ratio too high?
Connect Biopharma Holdings' current PB Ratio of 3.12 is near median its 10-year median of 3.13. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 4.64. The Biotechnology industry median PB Ratio is 2.80. Connect Biopharma Holdings' value of 3.12 is 11.4% above this industry median. Based on the distribution chart, Connect Biopharma Holdings ranks #670 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' PB Ratio compare to ANTX and VXRT?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #670 out of 1233 companies for PB Ratio. This places Connect Biopharma Holdings in the lower half of its industry. The industry median PB Ratio is 2.80. Connect Biopharma Holdings' value of 3.12 is 11.4% above this benchmark. Historically, Connect Biopharma Holdings' own PB Ratio has ranged from 1.21 to 4.64 over the past decade. While the company's 10-year median is 3.13 vs. the industry median of 2.80, Connect Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Connect Biopharma Holdings's current PB Ratio of 3.12 is 11.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Connect Biopharma Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Connect Biopharma Holdings's current PB Ratio is 3.12, which is near median its own 10-year median of 3.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current PB Ratio of 3.12. The current PB Ratio is 3.12, which is near median its 10-year median of 3.13 and 11.4% above the Biotechnology industry median of 2.80. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current PB Ratio is 3.12 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score
Get the complete analysis for CNTB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTB has been successfully added to your 
